Amy E.  McKee net worth and biography

Amy McKee Biography and Net Worth

Dr. McKee was appointed to the Board in September 2021. Dr. McKee currently serves as Senior Vice President of Oncology Regulatory Science, Strategy and Excellence at AstraZeneca, a global pharmaceutical company, where she joined after serving as Chief Medical Officer and Global Head, Oncology Center of Excellence for Parexel, a leading global clinical research organization. Prior to joining Parexel in 2019, Dr. McKee spent more than a decade at the US Food and Drug Administration (FDA) in leadership roles of increasing responsibility. She served as a primary reviewer of new drug applications (NDAs) and biologics license applications (BLAs) across multiple divisions and served as both the acting Deputy Director and supervisory Associate Director of the Office of Hematology and Oncology Products where she managed four separate divisions performing NDA and BLA reviews. From January 2018 through February 2019, Dr. McKee was the deputy Center Director for the FDA’s Oncology Center of Excellence, which helps expedite development of innovative medical products for oncologic and hematologic malignancies and supports an integrated approach to their clinical evaluation. Dr. McKee received a B.A. in Russian and East European studies from Middlebury College and received her M.D. from Tulane University School of Medicine. She was a clinical fellow at the National Cancer Institute/Johns Hopkins University in the pediatric hematology/oncology fellowship program.

What is Amy E. McKee's net worth?

The estimated net worth of Amy E. McKee is at least $206,784.33 as of June 24th, 2024. Dr. McKee owns 27,831 shares of BioCryst Pharmaceuticals stock worth more than $206,784 as of April 3rd. This net worth estimate does not reflect any other investments that Dr. McKee may own. Learn More about Amy E. McKee's net worth.

How do I contact Amy E. McKee?

The corporate mailing address for Dr. McKee and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Amy E. McKee's contact information.

Has Amy E. McKee been buying or selling shares of BioCryst Pharmaceuticals?

Amy E. McKee has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, Amy E. Mckee sold 8,600 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $6.32, for a transaction totalling $54,352.00. Following the completion of the sale, the director now directly owns 27,831 shares of the company's stock, valued at $175,891.92. Learn More on Amy E. McKee's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/24/2024.

Amy E. McKee Insider Trading History at BioCryst Pharmaceuticals

See Full Table

Amy E. McKee Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows Amy E Mckee's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40k-$20k$0$20k$40kTotal Insider BuyingTotal Insider Selling

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.43
Low: $7.15
High: $7.44

50 Day Range

MA: $8.17
Low: $7.25
High: $9.39

2 Week Range

Now: $7.43
Low: $4.03
High: $9.50

Volume

2,223,517 shs

Average Volume

2,771,435 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84